Indium (111In) igovomab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 58: | Line 58: | ||
{{antineoplastic-drug-stub}} | {{antineoplastic-drug-stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Latest revision as of 12:52, 18 March 2025
| Indium (111In) igovomab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 171656-50-1 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Indium (111In) igovomab (trade name Indimacis-125) was a mouse monoclonal antibody for the diagnosis of ovarian cancer.
(March 2012)
Linked to the chelating agent DTPA and labelled with Indium-111, it was used for imaging (radio-immuno scintigraphy) of the cancer.
(March 2012)
The drug is no longer available.<ref>Google books: Handbook of Therapeutic Antibodies, vol. 3</ref><ref>Biopharma: indium (111 In) igovomab - Indimacis 125</ref>
References[edit]
<references group="" responsive="1"></references>
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
